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Background. To investigate the relationship between hemagglutinin-inhibition (HI) antibody levels to the risk
of inﬂuenza disease, we conducted a correlate of protection analysis using pooled data from previously published
randomized trials.
Methods. Data on the occurrence of laboratory-conﬁrmed inﬂuenza and HI levels pre- and postvaccination were
analyzed from 4 datasets: 3 datasets included subjects aged <65 years who received inactivated trivalent inﬂuenza
vaccine (TIV) or placebo, and 1 dataset included subjects aged ≥65 years who received AS03-adjuvanted TIV (AS03-
TIV) or TIV. A logistic model was used to evaluate the relationship between the postvaccination titer of A/H3N2 HI
antibodies and occurrence of A/H3N2 disease. We then built a receiver-operating characteristic curve to identify a
potential cutoff titer between protection and no protection.
Results. The baseline odds ratio of A/H3N2 disease was higher for subjects aged ≥65 years than <65 years and
higher in seasons of strong epidemic intensity than moderate or low intensity. Including age and epidemic intensity
as covariates, a 4-fold increase in titer was associated with a 2-fold decrease in the risk of A/H3N2 disease.
Conclusions. The modeling exercise conﬁrmed a relationship between A/H3N2 disease and HI responses, but
it did not allow an evaluation of the predictive power of the HI response.
Keywords. A/H3N2; inﬂuenza; modeling; serologic correlates; vaccine.
Inactivated and recombinant protein inﬂuenza vaccines
are licensed based in part on immunogenicity data
because regulatory authorities assume postvaccination
hemagglutination-inhibition (HI) antibody titers above
a deﬁned threshold are predictive of clinical beneﬁt.
An HI titer threshold of 1:40 is generally recognized as
corresponding to a 50% reduction in the risk of inﬂuenza,
and this is based on a challenge study in adults conducted
by Hobson et al [1] in 1972. However, in the literature,
there is no consensus on the deﬁnition of “protection”,
with some studies deﬁning protection as a predeﬁned
risk reduction (usually 50%) and other studies deﬁning
protection as the titer levels that provide the best separa-
tion between inﬂuenza cases and noncases [2–5].
To identify and validate any immunological thresh-
old as a correlate of protection, it would be desirable
Received 19 November 2014; accepted 11 May 2015.
aPresent Afﬁliation: GSK Vaccines, Rixensart, Belgium.
Correspondence: Walthère Dewé, MSc, GSK Vaccines, Rue de l′Institut 89,
B-1330 Rixensart, Belgium (walthere.p.dewe@gsk.com).
Open Forum Infectious Diseases
© The Author 2015. Published by Oxford University Press on behalf of the Infectious
DiseasesSocietyofAmerica. This is anOpenAccessarticle distributedunder the terms
of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://
creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial
reproduction and distribution of the work, in any medium, provided the original work
is not altered or transformed in any way, and that the work is properly cited. For
commercial re-use, please contact journals.permissions@oup.com.
DOI: 10.1093/oﬁd/ofv067
Inﬂuenza Vaccine and Serologic Correlates of Protection • OFID • 1
 at Tam
pere U
niversity Library. D
epartm
ent of H
ealth Sciences on N
ovem
ber 17, 2016
http://ofid.oxfordjournals.org/
D
ow
nloaded from
 
for inﬂuenza efﬁcacy vaccine trials to be adequately and consis-
tently designed to allow correlate of protection (COP) analyses,
either within a single trial or after pooling of data across dif-
ferent trials. The ﬁndings of such analyses would increase the
clinical relevance of subsequent studies based on serologic
endpoints generated by the same laboratory and assay protocol.
Therefore, we pooled data from several trials to assess the
relevance of HI antibody levels for protection.
In this study, we describe a COP analysis of pooled data from
randomized trials of seasonal inﬂuenza vaccines including 7730
subjects [6–9]. In 1 trial, A/H3N2 was the most common inﬂu-
enza virus detected overall; therefore, this COP analysis focused
on A/H3N2 [9]. This multitrial approach supports the search
for an immunological measurement that is predictive of vaccine
efﬁcacy across various settings.
METHODS
Materials and Methods
The analysis was based on 2 trials in subjects aged 18–64 years, 1
trial in subjects aged 18–49 years, and 1 study in subjects aged
≥65 years. In each of these efﬁcacy studies, immunogenicity anal-
yses were performed on per-protocol immunogenicity subco-
horts (including subjects who met eligibility criteria, complied
with the protocol, received any dose of either vaccine or placebo,
and for whom data were available for a given endpoint). An over-
view of the trials is as follows. (1) Beran et al [6] performed a ran-
domized, double-blind, placebo-controlled study of the efﬁcacy
of trivalent inﬂuenza vaccine (TIV) against culture-conﬁrmed in-
ﬂuenza in healthy adults aged 18–64 years. A total of 5103 and
2549 subjects received TIV or placebo, respectively, during the
2006–2007 season in Czech Republic and Finland. The immuno-
genicity subcohort in our analysis included 291 and 148 subjects
in the TIV and placebo groups, respectively (ClinicalTrials.gov
NCT00363870). (2) Beran et al [7] performed a randomized,
double-blind, placebo-controlled study of the efﬁcacy of TIV
against culture-conﬁrmed inﬂuenza in healthy adults aged
18–64 years. A total of 4137 and 2066 subjects received TIV or
placebo, respectively, during the 2005–2006 season in the Czech
Republic. The immunogenicity subcohort in our analysis includ-
ed 632 and 315 subjects in the TIV and placebo groups, respec-
tively (ClinicalTrials.gov NCT00197223). (3) Jackson et al [8]
performed a randomized, double-blind, placebo-controlled efﬁ-
cacy study of TIV against culture-conﬁrmed inﬂuenza in healthy
adults aged 18–49 years. In this study, a total of 3783 and 3828
subjects received TIV or placebo, respectively, during the 2005–
2006 and 2006–2007 seasons in the United States. The immuno-
genicity subcohort in our analysis included 1298 and 216 subjects
in the TIV and placebo groups, respectively (ClinicalTrials.gov
NCT00216242). (4) The Inﬂuence65 trial was a randomized,
observer-blinded study of the relative efﬁcacy of AS03-TIV vs TIV
against polymerase chain reaction (PCR)-conﬁrmed inﬂuenza
in healthy adults aged ≥65 years. The study included 43 695
subjects from 15 countries who received AS03-TIV or TIV dur-
ing the 2008–2009 and 2009–2010 seasons. The immunogenic-
ity subset included 2422 and 2408 subjects in the AS03-TIV and
TIV groups, respectively, and this analysis included immunoge-
nicity data from the 2008–2009 season (ClinicalTrials.gov
NCT00753272) [9].
In the trials including adults aged 18–64 years and 18–49 years,
eligible subjects were healthy. In the Inﬂuence65 trial including
adults aged ≥65 years, subjects with comorbidities were eligible
for inclusion if they were ambulatory, their health was stable,
and they were without acute illness at the time of vaccination. In-
clusion and exclusion criteria and ethics statements for the trials
in this analysis have been previously published [6–9].
All vaccines were manufactured by GSK Vaccines. In the
placebo-controlled studies, subjects were randomized to receive
(1) 1 0.5 mL dose of TIV containing 15 μg each of the 3 hemag-
glutinin antigens (HAs) recommended by the World Health
Organization (WHO) for the given inﬂuenza season or (2) saline
placebo. In the Inﬂuence65 trial, subjects were randomized to re-
ceive one 0.7 mL dose of AS03-TIV or 0.5 mLTIV. Details of the
vaccines used in each study have been previously described [6–9].
Case Deﬁnitions and Laboratory Methods
There were differences among the trials, but they all followed
the same general protocol. During the study periods, subjects
were monitored for inﬂuenza-like illness (ILI) by active surveil-
lance (telephone contact/study center visit/home visits by study
personnel) and by passive surveillance (whereby subjects noti-
ﬁed the study center if they experienced ILI symptoms). Case
deﬁnitions in each study have been previously described [6–9].
Nasal and throat swabs were obtained from subjects reporting
ILI for the laboratory identiﬁcation of inﬂuenza viruses as previ-
ously described [6–8].
In all studies, serum samples were taken before vaccination and
21 days after vaccination for the assessment of serum antibodies
to each vaccine-homologous HA. All testing was performed at a
GSK’s laboratory (Laval, Canada and Dresden, Germany) accord-
ing to an established method [10]. The high-sensitivity HI assay
used 25 µL serum and 25 µL antigen from a solution concentrat-
ed at 4HAunits/50 µL (ie, 2 HAunits). The erythrocyte (chicken)
concentration was 0.45%. Hemagglutination-inhibition assay-
based antibody responses were described as the antilog of the
arithmetic mean of the log10-transformed titers (geometric
mean titers [GMTs]). A titer of 1:5 was assigned to samples with
a value below a cutoff titer of 1:10.
Statistical Analysis
The following variables were considered in our analyses: gender,
age, seasonal inﬂuenza vaccination history within 2 previous
years, A/H3N2 infection status by the end of the study
season, pre- (Day 0) and postvaccination (Day 21) HI titers
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against A/H3N2, prevaccination immunity state (ie, A/H3N2
HI titer ≥1:40), A/H3N2 epidemic intensity (“strong intensity”
or “low/moderate intensity”), and A/H3N2 disease occurrence.
In Beran et al [6, 7] and Jackson et al [8], the epidemic intensity
was based on the WHO inﬂuenza surveillance (FluNet) data-
base and by evaluating the magnitude of the epidemics in the
corresponding countries at the time the studies were conducted.
In the Inﬂuence65 trial, epidemic intensity was based on na-
tional surveillance data and attack rates in the study, as assessed
by the Adjudication Steering Committee for the inﬂuenza peak
season, including experts in the ﬁeld of inﬂuenza and inﬂuenza
vaccination who were independent of the study investigators
and the study sponsor.
In the descriptive analysis, the distribution of variables was
characterized. For continuous variables, the number of observa-
tions, mean, standard deviation, and minimum and maximum
values were computed. For HI titers, GMTs and their coefﬁcient
of variation were also calculated after a log10 transformation.
Frequency statistics, including counts and proportions were
obtained for the categorical variables. A preliminary graphical
analysis was performed to assess each covariate versus A/H3N2
attack rates. The proportion of subjects with laboratory-
conﬁrmed A/H3N2 inﬂuenza was calculated for each dilution
factor of the postvaccination HI response against A/H3N2.
A logistic regression model was used to assess the effect of
covariates on A/H3N2 disease occurrence. The following covar-
iates were considered: prevaccination immunity state (titer
≥1:40 deﬁned as protected), Day 21 postvaccination A/H3N2
log10 titers, gender, history of vaccination (vaccination 1 and
2 years before study start), vaccine received, and age (Inﬂu-
ence65 trial ≥65 years vs other trials <65 years). The epidemic
intensity was also included in the model as a potential effect
modiﬁer because the protection level associated to a particular
HI titer could depend on the level of exposure [11]. A manual
stepwise variable selection was performed based on the Baye-
sian information criterion to select the best combination of co-
variates to describe the disease occurrence. One of the objectives
of our analysis was to try to identify the HI titer that best sep-
arates the subjects who were protected from those who were not.
A receiver-operating characteristic (ROC) curve, presenting the
sensitivity against one minus the speciﬁcity at various A/H3N2
HI titer cutoff values, was derived. Sensitivity was deﬁned as the
proportion of subjects with a postvaccination titer below the
cutoff value among those with conﬁrmed A/H3N2 inﬂuenza;
speciﬁcity was deﬁned as the proportion of subjects with a post-
vaccination titer equal to or greater than the cutoff value among
those without conﬁrmed A/H3N2 inﬂuenza. The Youden index,
identifying the lowest titer at which the sum of the speciﬁcity
and sensitivity was maximum, was used to assess such a thresh-
old [12]. The ROC area under the curve quantiﬁes the overall
ability of the test to discriminate between those individuals
with A/H3N2 disease and those without disease; it represents
the probability that a randomly selected inﬂuenza case will
have a lower result (estimation from the model taking into
account all selected covariates) than a randomly selected subject
without disease. Because the noncases were a mixture of pro-
tected subjects and not sufﬁciently exposed or nonprotected
subjects, we also derived a cutoff postvaccination titer value giv-
ing more weight to the cases detected, which we deﬁned as the
HI titer cutoff values for the detection of A/H3N2 inﬂuenza
with 90% sensitivity.
RESULTS
Descriptive Analysis
An overview of subjects included in the analysis is shown in
Figure 1. The demographic characteristics and GMTs for subjects
included in the analysis by trial are shown in Table 1. Pre- and
Figure 1. Overview of analysis population (descriptive analysis). Abbreviation: TIV, inactivated trivalent inﬂuenza vaccine.
Inﬂuenza Vaccine and Serologic Correlates of Protection • OFID • 3
 at Tam
pere U
niversity Library. D
epartm
ent of H
ealth Sciences on N
ovem
ber 17, 2016
http://ofid.oxfordjournals.org/
D
ow
nloaded from
 
postvaccination GMTs in subjects who received TIV or AS03-
TIV were 14.03–17.4 and 172.3–285.6, respectively, and in sub-
jects who received placebo were 14.12 and 14.14, respectively.
Prevaccination, 5405 (71.1%) subjects had an antibody titer
against A/H3N2 that was <1:40 (Supplementary Data 1) and
2309 (29.9%) had a titer that was ≥1:40. Sixteen subjects aged
≥65 years did not have prevaccination titer data available.
The A/H3N2 disease rates by age and epidemic intensity are
shown in Table 2. The frequency of A/H3N2 cases and postvac-
cination HI titers against A/H3N2 are shown in Figure 2,
among which 1098 and 6632 subjects, respectively, had postvac-
cination titers of <1:40 and ≥1:40. Of 1098 of 7730 (14.2%) sub-
jects with postvaccination HI titers of <1:40, 24 of 1098 (2.2%)
subjects had conﬁrmed A/H3N2 disease; among 6632 of 7730
(85.8%) subjects with postvaccination titers of ≥1:40, 50 of 6632
(0.75%) had conﬁrmed A/H3N2 disease.
Logistic Regression Analysis
Table 3 shows the parameter estimates used in the selected mod-
els, which includes postvaccination HI titers, epidemic intensity,
and age as covariates. The odds ratio for A/H3N2 disease in high
versus moderate or low epidemic intensity was 3.4 (95% conﬁ-
dence interval [CI], 2.1–5.6). The odds ratio of A/H3N2 disease
in subjects aged≥65 years vs <65 years was 3.5 (95% CI, 1.9–6.3).
Including postvaccination HI titer and age as covariates, the odds
ratio for A/H3N2 disease in subjects aged ≥65 years vs <65 years
was 4.2 (95% CI, 2.3–7.8).
In the full model, including epidemic intensity and age catego-
ry, a 4-fold increase in postvaccination HI titer was associated
with a 49.0% decrease in the risk of infection, and including
only age category as a covariate, a 4-fold increase in titer was
also associated with a 49.4% decrease in the risk of infection. Con-
sistency of the HI response across the HI range was an assumption
of the statistical model, which appeared acceptable based on the
cases and HI titers observed (Figure 3).
The area under the curve for the ROC including age and sea-
son strength as covariates was estimated at 0.7735 (Supplemen-
tary Data 2). The Youden index HI titer cutoffs and the 90%
sensitivity cutoff values are shown in Table 4.
DISCUSSION
In agreement with previous reports, we found a correlation be-
tween HI titers and the risk of A/H3N2 disease [1, 13]. Includ-
ing age and epidemic intensity as covariates, we showed that a
4-fold increase in titer was associated with a 2-fold decrease in
the risk of A/H3N2 disease, with a similar difference in risk ob-
served when including only age as a covariate. The Youden
index cutoff values in a season of high epidemic intensity
were 1:40 and 1:640 in subjects aged <65 years and ≥65 years,
Table 1. Demographic Characteristics and A/H3N2 HI Antibody Titers Prevaccination (Day 0) and Postvaccination (Day 21) (Descriptive
Analysis)
Adults aged 18–64 years [6–8] Adults aged ≥65 years [9]
TIV N = 2221 Placebo N = 679 AS03-TIV N = 2422 TIV N = 2408
Mean age (SD) range, years 35.78 (12.2) 18–64 34.53 (11.3) 18–64 73.2 (6.0) 65–95 73.4 (6.3) 65–100
Vaccination history, n (%)
1 yr 243 (10.9%) 81 (11.9%) 1647/2197 (75.0%) 1650/2199 (75.0%)
2 yr 187 (8.4%) 32 (4.7%) 1569/2119 (74.0%) 1578/2127 (74.2%)
GMT, (range)
Day 0 14.03 (5–1810) 14.12 (5–640) 17.4 (5–1810) 17.4 (5–1280)
Day 21 178.61 (5–7240) 14.14 (5–905) 285.6 (5–20480) 172.3 (5–20480)
Abbreviations: AS03, tocopherol-based oil-in-water Adjuvant System; GMT, geometric mean titer; HI, hemagglutination inhibition; n, number of subjects fulfilling
definition; N, number of subjects in group; SD, standard deviation; TIV, inactivated trivalent influenza vaccine.
Table 2. A/H3N2 Infection Rates by Age and Epidemic Intensity in Subjects Pooled From 4 Vaccine Efﬁcacy Trials (Per-protocol Immu-
nogenicity Subcohorts) (Descriptive Analysis)
Age Epidemic Intensity Subjects A/H3N2 Cases Infection Rate (%)
≥65 yr McElhaney et al [9] Low or moderate 2939 20 0.68
High 1891 40 2.12
18–64 yr Beran et al [6, 7] Jackson et al [8] Low or moderate 1873 4 0.21
High 1027 10 0.97
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respectively. Although we found that age did not appear to
affect the serological response to vaccination based on GMTs,
older subjects seemed to have a greater risk of infection at
similar titers compared with younger subjects.
Although age deﬁned the population studied in each trial
included in the analysis, case detection methods and circulat-
ing viruses may affect the susceptibility of a population to in-
ﬂuenza disease. In addition, because these factors differed
between the trials, the effect of age on HI titers as a COP
must be interpreted with caution. Indeed, there are several
factors related to the differences among the trials that are
confounded in our analysis: the nature of the comparison
(placebo or active treatment, adjuvanted or not), inﬂuenza
case deﬁnitions, laboratory methods for viral detection (cul-
ture or PCR), HI measurements, and the age of participants
(18–64 years, 18–49 years, ≥65 years). In addition, cell-
mediated immunity contributes to protection against inﬂuen-
za, but the reliability of the HI titer as an index of both
humoral and cellular immunity is unknown and likely to differ
with advancing age. We believe that the most important differ-
ences among the trials were the differences in the population
studied reﬂected by age, which is a surrogate for unmeasured
Figure 2. Number of subjects in each titer category and number of A/H3N2 cases (A) and proportion of subjects in each titer category with laboratory-
conﬁrmed A/H3N2 infection (B) (descriptive analysis).
Table 3. Estimates of the Logistic Regression Model Parameters
Parameter Estimate P Value Odds Ratio 95% Confidence Interval on the Odds Ratio
Baseline risk for the reference categorya −3.922 <.0001
Postvaccination log titer −1.1199 <.0001 0.3263 .2311, .4607
Epidemic intensity 1.2366 <.0001 3.4439 2.0995, 5.6491
Age as covariatesb 1.2388 .0001 3.4515 1.8863, 6.3154
a Null postvaccination titer, low moderate epidemic intensity, and <65 years.
b Trial (Influence65 trial [≥65 years] vs other trials [<65 years])/age (≥65 vs <65).
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differences in immunity based on past exposure, and differ-
ences in the deﬁnition of inﬂuenza disease.
Inﬂuenza occurrence depends upon the immunity of a given
population as well as their exposure to circulating viruses.
Because different countries have different vaccination policies
that inﬂuence the transmission and exposure to viruses (eg, vac-
cination of children), we included epidemic intensity as a covar-
iate based on surveillance in each country as an indicator of
exposure. However, exposure may also change the level of
antibody needed to prevent illness of any severity [11]. This is
an important concept because in adults, most illnesses are rel-
atively mild, but the occurrence of severe illness resulting in
hospitalization and adverse outcomes increases with advancing
age. In this pooled analysis, we did not have a systematic pro-
spective classiﬁcation of moderate to severe illness, and because
the level of antibody correlating with protection against moder-
ate to severe illness may be less than that needed to protect
against mild illness, our analysis may be confounded. In addi-
tion, regional and seasonal variability of circulating viruses and
variations in the severity of inﬂuenza illness are difﬁcult to ac-
count for in a COP analysis.
An objective of our analysis was to try to identify the HI titer
that best separates the 2 subject groups—protected and not pro-
tected. By considering a ROC approach, selecting a cutoff point
involves a trade-off between sensitivity and speciﬁcity. The You-
den index gives the same weight to both sensitivity and speciﬁcity
because it deﬁnes the cutoff point as the titer value that maximiz-
es the sum of the sensitivity and speciﬁcity [12]. The Youden
index method depends upon the separability of the protected
and nonprotected populations. However, the rate of infection
among subjects with low titers may be strongly associated with
the chance of exposure and disease prevalence, which vary
among seasons and locations as well as social behavior. There-
fore, the HI titer density curves for subjects whowere not infected
are a mixture of subjects who were protected and those who were
possibly unprotected but also unexposed. The methodology we
used relies on the belief that false negatives are likely to occur,
and thus sensitivity (true cases) should determine the cutoff
value. We reported the cutoff for 90% sensitivity, which was
1:453 in subjects <65 years and 1:5120 in subjects aged ≥65
years in a season of high epidemic intensity. This means that
subject with a higher prevaccination risk (ie, older subjects)
will need higher antibody titers to have the same level of protec-
tion as subjects with a lower prevaccination risk such that our
model provides varying cutoff points for protection.
Further methods used to assess inﬂuenza vaccine protection
include the scaled logistic regression model suggested by
Dunning [14] in which the probability of the subject developing
inﬂuenza is the probability that the subject is susceptible
to inﬂuenza multiplied by the probability that susceptible
Figure 3. A/H3N2 HI antibody titer and estimated risk of A/H3N2 inﬂu-
enza disease in subjects aged ≥65 years in an epidemic of low to moder-
ate intensity (A) or high intensity (B), and in subjects aged <65 years in an
epidemic of low to moderate intensity (C ) or high intensity (D). Dots
represent the observed proportions of cases and shading shows 95% con-
ﬁdence interval (logistic regression). Abbreviation: HI, hemagglutination
inhibition
Table 4. Youden Index Cutoff and 90% Sensitivity Cutoff Values
for A/H3N2 Hemagglutination Inhibition Antibody Titers (Logistic
Regression)
Age
Season
Strength
Youden Index
Cutoff Titer
90% Sensitivity
Cutoff Titer
<65 yr Low/moderate 1:5 1:28
<65 yr High 1:40 1:453
≥65 yr Low/moderate 1:40 1:453
≥65 yr High 1:640 1:5120
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individuals develop disease. In addition, Li et al [15] developed
a dichotomization method based on the maximization of the
correlation between the 2 populations and the dichotomous
variable. In the noncases population, the methods included a
parameter deﬁning the probability that the observation arises
from the case population (unprotected but not exposed).
In our logistic regression model, we found that the risk of dis-
ease was higher for older than younger subjects (prevaccination
risk) and higher in a season of high epidemic intensity than
moderate or low epidemic intensity. Subjects with a greater
risk (ie, older subject and/or in a strong epidemic intensity)
will need higher antibody titers to have the same level of protec-
tion as subjects with a lower risk (prevaccination or linked to
the season), meaning that our model provides varying cutoff
points for protection. We did not ﬁnd a signiﬁcant interaction
between postvaccination titers and subject-related covariates,
although the study lacks power. However, we found a similar
relationship to that reported in the literature: a four-fold in-
crease in postvaccination titers was associated with a 2-fold de-
crease in the risk of infection.
CONCLUSIONS
The statistical modeling exercise conﬁrmed that there is a rela-
tionship between the occurrence of A/H3N2 disease and HI an-
tibody responses but did not allow us to evaluate the predictive
power of the HI response. An alternative to performing pooled
analyses is to conduct inﬂuenza vaccine efﬁcacy trials that are de-
signed to provide data for COP analyses. In addition to ac-
counting for age and epidemic intensity, optimizing the
COP model would involve collecting serum samples from all
participants, rather than from a subcohort, identifying inﬂu-
enza disease based on a consistent case deﬁnition, and using
a consistent laboratory method for viral subtyping. The anal-
ysis should also take into account inﬂuenza disease severity
and the level of antigenic mismatch between the infecting
virus and the vaccine strains.
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Supplementary material is available online at Open Forum Infectious Diseas-
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